[Genetic engineering potential and perspectives in the management of critical ischemia].
The paper presents a new approach to management of lower limb critical ischemia which implements recent advances in molecular biology and genetic engineering technologies. A new original compound incorporating angiogenin gene was developed to activate neoangiogenesis processes after injection into living tissues. Experimental data evidence a potential efficacy of new method for complex management of critical ischemia.
Konstantinov
B A
BA
Department of Vascular Surgery, Russian Research Center of Surgery, Russian Academy of Medical Sciences, Moscow, Russia.
Bochkov
N P
NP
Gavrilenko
A V
AV
Voronov
D A
DA
Tarantul
V Z
VZ
Sheremet'eva
G F
GF
Skrylev
S I
SI
Khaĭdarova
N V
NV
D000818:Animals; D002642:Chick Embryo; D002908:Chronic Disease; D004274:DNA, Recombinant / Q000235:genetics; D005822:Genetic Vectors / Q000235:genetics; D007511:Ischemia / Q000235:genetics* / Q000601:surgery / Q000628:therapy*; D035002:Lower Extremity / Q000098:blood supply*; D008297:Male; D018919:Neovascularization, Physiologic / Q000502:physiology; D010957:Plasmids / Q000235:genetics; D015202:Protein Engineering / Q000379:methods*; D051381:Rats; D017208:Rats, Wistar; D012259:Ribonuclease, Pancreatic / Q000235:genetics* / Q000627:therapeutic use*; D014656:Vascular Surgical Procedures / Q000379:methods
D004274:DNA, Recombinant; C046366:angiogenin; D012259:Ribonuclease, Pancreatic